Diuretic antihypertensive drugs and incident dementia risk: A systematic review, meta-analysis and meta-regression of prospective studies

Journal of Hypertension

Volumn 34, Issue 6, 2016, Pages 1027-1035

  Tully, Phillip J ^a,b,e   Hanon, Olivier ^c   Cosh, Suzanne ^d   Tzourio, Christophe ^a,e  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c INSERM   (France)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e CNRS   (France)

Author keywords

Alzheimer disease; carbonic anhydrase inhibitors; dementia; diuretics; hypertension; potassium sparing diuretics; sodium chloride symporter inhibitors; vascular dementia

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; DIURETIC AGENT; LOOP DIURETIC AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ALLELE; ALZHEIMER DISEASE; CEREBROVASCULAR ACCIDENT; COGNITION; DATA BASE; DEMENTIA; DEMOGRAPHY; DIABETES MELLITUS; FOLLOW UP; HEART FAILURE; HUMAN; LIVER DISEASE; META ANALYSIS; MORTALITY RATE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; HYPERTENSION; PROTECTION;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; DEMENTIA; DIURETICS; DIURETICS, POTASSIUM SPARING; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84958793938     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000868     Document Type: Review

References (56)

1. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265:3255-3264.
2. Chang-Quan H, Hui W, Chao-min W, Zheng-Rong W, Jun-Wen G, Yong-Hong L, et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011; 65:1295-1305.
3. Forette F, Seux M-L, Staessen JA, Thijs L, Birkenhager WH, Babarskiene M-R, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347-1351.
4. Goh KL, Bhaskaran K, Minassian C, Evans SJ, Smeeth L, Douglas IJ. Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink. Br J Clin Pharmacol 2015; 79:337-350.
5. Levi Marpillat N, Macquin-Mavier I, Tropeano A-I, Bachoud-Levi A-C, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013; 31:1073-1082.
6. Yasar S, Xia J, Yao W, Furberg CD, Xue Q-L, Mercado CI, et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 2013; 81:896-903.
7. Peters R, Booth A, Peters J. A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. J Hypertens 2014; 32:1945-1957.
8. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7:683-689.
9. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al. Reninangiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011; 10:43-53.
10. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ 1999; 161:501-506.
11. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag 2010; 6:775-785.
12. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev (4):2009;CD004034.
13. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs 2015; 29:113-130.
14. Guan JW, Huang CQ, Li YH, Wan CM, You C, Wang ZR, et al. No association between hypertension and risk for Alzheimers disease: a meta-analysis of longitudinal studies. J Alzheimers Dis 2011; 27:799-807.
15. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 2005; 229- 230:151-155.
16. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens 2006; 24:1907-1914.
17. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7:250-261.
18. Moser M, Feig PU. Fifty years of thiazide diuretic therapy for hypertension. Arch Intern Med 2009; 169:1851-1856.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
21. Blacher J, Halimi J-M, Hanon O, Mourad J-J, Pathak A, Schnebert B, et al. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol 2014; 28:1-9.
22. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 5:CD003824.
23. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
24. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075.
25. Chuang Y-F, Breitner JCS, Chiu Y-L, Khachaturian A, Hayden K, Corcoran C, et al. Use of diuretics is associated with reduced risk of Alzheimers disease: the Cache County Study. Neurobiol Aging 2014; 35:2429-2435.
26. Ozawa M, Ninomiya T, Ohara T, Hirakawa Y, Doi Y, Hata J, et al. Selfreported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. J Am Geriatr Soc 2012; 60:1515-1520.
27. Rastas S, Pirttila T, Mattila K, Verkkoniemi A, Juva K, Niinisto L, et al. Vascular risk factors and dementia in the general population aged >85 years. Prospective population-based study. Neurobiol Aging 2010; 31:1-7.
28. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/ american stroke association. Stroke 2011; 42:2672-2713.
29. Lu N, Dubreuil M, Zhang Y, Neogi T, Rai SK, Ascherio A, et al. Gout and the risk of Alzheimers disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 2015; (in press).
30. Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain 2009; 132 (Pt 2):377-382.
31. Lin CS, Lee WL, Hung YJ, Lee DY, Chen KF, Chi WC, et al. Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan. Int J Cardiol 2012; 156:41-46.
32. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700.
33. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol 2012; 65:163-178.
34. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schunemann HJ, GRADE Working Group. Rating quality of evidence and strength of recommendations: Going from evidence to recommendations. BMJ 2008; 336:1049-1051.
35. Loef M, Walach H. The combined effects of healthy lifestyle behaviors on all cause mortality: a systematic review and meta-analysis. Prev Med 2012; 55:163-170.
36. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 2002; 55:893-899.
37. Haag MDM, Hofman A, Koudstaal PJ, Breteler MMB, Stricker BHC. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology 2009; 72:1727-1734.
38. Morris M, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58:1640-1646.
39. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Chichester, West Sussex, UK: John Wiley and Sons Ltd; 2008.
40. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63:686-692.
41. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
42. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
43. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455-463.
44. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
45. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999; 56:991-996.
46. Int Veld BA, Ruitenberg A, Hofman A, Stricker BHC, Breteler MMB. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22:407-412.
47. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimers disease in Japan. J Am Geriatr Soc 2004; 52:649-650.
48. The 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiol 2003; 22:316-325.
49. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old the 90 study. Ann Neurol 2010; 67:114-121.
50. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277:739-745.
51. Al-khateeb E, Althaher A, Al-khateeb M, Al-Musawi H, Azzouqah O, Al- Shweiki S, et al. Relation between uric acid and Alzheimers disease in elderly Jordanians. J Alzheimers Dis 2015; 44:859-865.
52. Reyes AJ. Heart failure, dementia, and diuretics: is uric acid involved? Arch Intern Med 2006; 166:2286.
53. Mousavi M, Jonsson P, Antti H, Adolfsson R, Nordin A, Bergdahl J, et al. Serum metabolomic biomarkers of dementia. Dement Geriatr Cogn Dis Extra 2014; 4:252-262.
54. Tamargo J, Segura J, Ruilope LM, Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 2014; 15:605-621.
55. Ashby EL, Kehoe PG. Current status of renin-aldosterone angiotensin system-targeting antihypertensive drugs as therapeutic options for Alzheimers disease. Expert Opin Investig Drugs 2013; 22:1229-1242.
56. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340:b5465.